TOKYO, Apr 24 (Pulse News Wire) – Renascience Inc. (4889.T) initiated a Phase II trial targeting locally advanced non-small cell lung cancer (NSCLC) with its PAI-1 inhibitor RS5,614.
The study, led by Hiroshima University, involves 27 patients and aims to evaluate the efficacy and safety of combining RS5,614 with chemoradiotherapy and durvalumab consolidation therapy. Registration began in April 2026 and is expected to continue until March 2028, with observations concluding in June 2029. Previously conducted trials showed enhanced anti-tumor effects when RS5,614 was combined with nivolumab and durvalumab.
This new trial focuses on early-stage locally advanced NSCLC patients who undergo initial standard treatments such as chemoradiotherapy followed by immunotherapy. The goal is to improve treatment outcomes while mitigating radiation-induced lung damage. Funding for the trial comes from the Japan Agency for Medical Research and Development (AMED).
Although costs are lower than initially anticipated due to AMED funding, expenses related to the project will be included in Renascience's fiscal year 2027 earnings forecast.
🟢 Confidence: High AI-translated content.